Stocks Funds Screener Sectors Watchlists

SWTX - SpringWorks Therapeutics Inc Stock Price, Fair Value and News

$46.99

Market Closed as of 02 Jul 2025, 04:00 pm ET

SWTX Stock Valuation Analysis

Valuation

Max Portfolio %

SWTX Price Action

SWTX RSI Chart

SWTX Stock Valuation Analysis

Valuation

Max Portfolio %

SWTX Valuation

SWTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SWTX Fundamentals

SWTX Revenue

SWTX Earnings

SWTX Profitability

SWTX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	219.7M	0	0	0
2024	52.0M	98.5M	145.1M	191.6M
2023	7.2M	13.0M	18.3M	5.4M
2022	7.8M	960.0K	1.7M	0
2021	28.2M	21.4M	14.6M	0
2020	0	3.1M	2.2M	35.0M
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

CEO	Mr. Saqib Islam J.D.
WEBSITE	springworkstx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	227